Clinical Trial Detail

NCT ID NCT02900664
Title A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

non-small cell lung carcinoma

triple-receptor negative breast cancer

Therapies

PDR001 + Nazartinib

PDR001 + CJM112

PDR001 + Trametinib

PDR001 + Canakinumab

Age Groups: adult senior

Additional content available in CKB BOOST